Associate Prof Jeremy Lim’s primary role is as CEO and Co-Founder of AMILI, a microbiome insights company based in Singapore serving the region. Beyond this, he also undertakes academic and practice-focused work in health financing. In previous roles, Jeremy has spent substantial time in public and private healthcare across Asia as well as in policy advisory with Singapore and other regional governments, the Asian Development Bank, the World Bank and the World Health Organization. He was founding Partner in NYSE-listed Oliver Wyman’s Asia healthcare consulting practice.
He is also an adjunct faculty in the National University of Singapore and Monash University Malaysia.
Outside academia, Jeremy serves on the boards of various for-profit and not-for-profit organizations in different aspects of healthcare including hospitals, migrant worker health, healthy longevity and digital health interventions. He maintains an active interest in health advisory, supporting former clients, focusing mainly on healthcare acquisitions and health insurance.
He trained in surgery and public health, attaining post-graduate qualifications in both from the UK and US.
Jeremy Lim现任 AMILI 公司联合创始人兼首席执行官，公司总部位于新加坡，专注微生物领域研究与应用，服务于整个亚洲区域。除企业管理工作外，他也长期从事健康融资方向的学术研究与实践探索。
Jeremy 拥有丰富的亚洲公共与私营医疗体系从业经验，并曾为新加坡及其他亚洲国家政府、亚洲开发银行、世界银行与世界卫生组织提供政策咨询服务。此前，他是Oliver Wyman 亚洲医疗咨询业务的创始合伙人。
Jeremy受过外科学与公共卫生的系统培训，在英国与美国获得相关研究生学位与专业资格，并担任新加坡国立大学与马来西亚蒙纳士大学的兼职教授。在学术研究之外，还活跃于多个医疗相关领域的机构董事会，包括医院、劳工健康、长寿与数字医疗干预等。